In this review:
MetMab + erolinib in advanced NSCLC
Erlotinib benefits EGFR-mutant Caucasians
Denosumab improves survival in lung cancer
Amrubicin in 2nd-line treatment of SCLC
Cisplatin dose in advanced NSCLC
Optimising first-line CT plus cetuximab
Continued pemetrexed
Please login below to download this issue (PDF)